Month: March 2025

SOUTH SAN FRANCISCO, Calif., March 03, 2025 (GLOBE NEWSWIRE) — Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that it will report the Company’s fourth quarter 2024 financial results on Monday, March 10, 2025, before the open of the U.S. financial markets. About Aligos Aligos Therapeutics, Inc. (NASDAQ: ALGS) is a clinical stage biopharmaceutical company founded with the mission to improve patient outcomes by developing best-in-class therapies for the treatment of liver and viral diseases. Aligos applies its science driven approach and deep R&D expertise to advance its purpose-built pipeline of therapeutics with high unmet medical needs such as chronic hepatitis B virus infection,...

GREENWICH, Conn., March 03, 2025 (GLOBE NEWSWIRE) — Gabelli Funds is hosting its 16th Annual Specialty Chemicals Symposium taking place at The Harvard Club in New York, NY on Thursday, March 20, 2025.  The symposium will draw a variety of companies, with a focus on pricing power, margin recovery, interest rates, inventory stabilization, global trade policy, demand trends, and the M&A environment.  Attendees will also have the opportunity to meet with managements in a one-on-one setting. Agenda:8:20am Opening Remarks Rosemarie Morbelli, CFA Gabelli Funds    Wayne Pinsent, CFA Gabelli Funds     8:30 Cabot Corporation (NYSE: CBT)* To Be Confirmed          9:00 Arq, Inc. (NASDAQ: ARQ) Bob Rasmus, President & CEO          9:30 BASF Corporation (XETRA: BAS.DE) Alex Koehler, Investor Relations          10:00 American...

Andrea White Named Chief Human Resources Officer of SonocoAndrea White Sonoco Chief Human Resources OfficerHARTSVILLE, S.C., March 03, 2025 (GLOBE NEWSWIRE) — Sonoco Products Company (NYSE: SON), a global leader in high-value sustainable packaging, announced that Andrea White, has been named Chief Human Resources Officer and has been elected a corporate officer by the Company’s Board of Directors. She is a member of the Company’s Executive Committee and reports to Howard Coker, President and CEO. White, 50, is an 18-year Sonoco veteran beginning her career as a Reliability Engineer after working in Manufacturing and Process Improvement for Milliken & Company for over a decade. She quickly expanded her roles within the Company to serve as a Global Maintenance Excellence Manager before assuming the position of Director,...

CARLSBAD, Calif., March 03, 2025 (GLOBE NEWSWIRE) — Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that management will participate in a fireside chat during Leerink’s Global Healthcare Conference on Monday, March 10, 2025, at 1:40 p.m. ET in Miami. A live webcast of the fireside chat will be available here and in the investors section of the company’s website at www.designtx.com. The webcast will be archived for at least 30 days following the presentation. About Design TherapeuticsDesign Therapeutics is a clinical-stage biotechnology company developing a new class of therapies based on its platform of GeneTAC® gene targeted chimera small molecules. The company’s GeneTAC® molecules are designed to either dial up or...

– Esperion to Receive an Upfront Payment and Near-Term Milestones Along with a Profitable Transfer Price on Product Sales – ANN ARBOR, Mich., March 03, 2025 (GLOBE NEWSWIRE) — Esperion Therapeutics (NASDAQ: ESPR) today announced it has entered into a license and distribution agreement with CSL Seqirus (ASX:CSL) for the exclusive rights to commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Australia and New Zealand. Under the terms of the agreement, Esperion will receive an upfront and near-term milestone payments and will be responsible for supplying finished product to CSL Seqirus at a profitable transfer price. In Australia, cardiovascular disease affects 1.2 million people and is a leading cause of death. In New Zealand, an estimated 175,000 adults are living with cardiovascular disease,...

REDWOOD CITY, Calif., March 03, 2025 (GLOBE NEWSWIRE) — Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity medicines company, today announced that on March 3, 2025, the compensation committee of Biomea’s board of directors granted one new employee non-qualified stock options to purchase an aggregate of 25,000 shares of the Company’s common stock. The shares underlying the employee’s stock options will vest 1/16 on a quarterly basis over four years, subject to the employee’s continued employment with the Company on such vesting dates. The above-described award was made under Biomea’s 2023 Inducement Equity Plan (the “Plan”). The above-described award was granted as an inducement material to the employee entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4) and...

NEW YORK, March 03, 2025 (GLOBE NEWSWIRE) — Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to developing small-molecule medicines for brain conditions with significant unmet need, today announced the appointment of Stelios Papadopoulos, Ph.D. to its Board of Directors. “Stelios is a pioneering force in biotechnology. His vision and strategic acumen have shaped the landscape of our industry—building companies, financing breakthroughs, and enabling transformative medicines. We are honored to welcome him to our Board at a defining moment for Ovid,” said Jeremy Levin, D.Phil, MB BChir, Chairman and CEO of Ovid Therapeutics. “With our advancing pipeline, including our novel KCC2 direct activators and OV329 epilepsy program, Ovid stands on the cusp of delivering real change for neurological and psychiatric...

─Completed Successful FDA End-of-Phase 2 Meeting Following Positive Nebokitug Phase 2 SPRING Trial Results in Primary Sclerosing Cholangitis (PSC)─ ─Achieved Alignment with FDA on Clear and Efficient Pathway to Potential Regulatory Approval for the Treatment of PSC with No Liver Biopsies or Confirmatory Studies Needed; Nebokitug Positioned to Potentially Become the First FDA-Approved Treatment for PSC─ ─On Track for Releasing Clinical Data from SPRING Trial Open Label Extension in First Quarter 2025─ ─Discussions with Potential Strategic Partners Ongoing─ TEL AVIV, Israel, March 03, 2025 (GLOBE NEWSWIRE) — Chemomab Therapeutics Ltd. (Nasdaq:CMMB), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced financial and operating results for the...

DURHAM, N.C., March 03, 2025 (GLOBE NEWSWIRE) — Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced it will host an in-person and virtual investor event in New York on Thursday, March 6, 2025 at 12:00 PM ET. To register as an in-person or virtual attendee, please click here. The event will feature vascular surgery key opinion leaders (KOLs) Michael Curi, MD, MPA (Rutgers New Jersey Medical School) and Sammy Siada, DO, FACS, RPVI (UCSF Fresno), who will join company management to discuss the commercial plans and early market-launch success of Symvess (acellular tissue engineered vessel-tyod) for extremity arterial injury. Symvess is a first-in-class bioengineered human tissue designed to be a universally...

SOUTH SAN FRANCISCO, Calif., March 03, 2025 (GLOBE NEWSWIRE) — Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that Faraz Ali, Tenaya’s Chief Executive Officer, will participate in TD Cowen’s 45th Annual Health Care Conference and the Leerink Partners Global Healthcare Conference 2025. Details are as follows: TD Cowen 45th Annual Health Care ConferenceDate: Tuesday, March 4Time: 1:10 PM ET – 1:40 PM ETFormat: Company Presentation Leerink Partners Global Healthcare Conference 2025Date: Wednesday, March 12Time: 8:40 AM ET – 9:10 AM ETFormat: Fireside Chat The live and archived webcast of the presentation and fireside chat may be accessed from the Investors...